A Study to Evaluate the Effect of High Fat Meal on Cabotegravir

Inclusion Criteria:

- An eligible subject should be between 18 to 65 years of age inclusive, at the time of
signing the informed consent

- Healthy as determined by a responsible and experienced physician, based on a medical
evaluation including medical history, physical examination, laboratory tests, and
cardiac monitoring.

- A subject with a clinical abnormality or laboratory parameter(s) which is/are not
specifically listed in the inclusion or exclusion criteria, outside the reference
range for the population being studied may be included only if the investigator in
consultation with the medical monitor if required agree and document that the finding
is unlikely to introduce additional risk factors and will not interfere with the
study procedures.

- Body weight >= 50 kilograms (kg) and body mass index (BMI) within the range 18.5 to
31.0 kilograms per squared meter (kg/m^2) (inclusive).

- Male or female subjects. A female subject is eligible to participate if she is not
pregnant (as confirmed by a negative serum or urine human chorionic gonadotrophin
[hCG] test), not lactating, and at least one of the following conditions applies:

1. Non reproductive potential defined as:

Pre menopausal females with one of the following:

- Documented tubal ligation

- Documented hysteroscopic tubal occlusion procedure with follow up
confirmation of bilateral tubal occlusion

- Hysterectomy

- Documented bilateral oophorectomy

- OR has only same sex partners, when this is her preferred and usual
lifestyle Post menopausal is defined as 12 months of spontaneous amenorrhea
(in questionable cases a blood sample with simultaneous follicle
stimulating hormone [FSH] and estradiol levels consistent with menopause).
Females on hormone replacement therapy (HRT) and whose menopausal status is
in doubt will be required to use one of the highly effective contraception
methods if they wish to continue their HRT during the study. Otherwise,
they must discontinue HRT to allow confirmation of post menopausal status
prior to study enrolment

2. Reproductive potential and agrees to follow one of the options listed in the
modified list of highly effective methods for avoiding pregnancy in females of
reproductive potential (FRP) from 30 days prior to the first dose of the study
medication and until after the last dose of the study medication and completion
of the follow up visit. The investigator is responsible for ensuring that
subjects understand how to properly use these methods of contraception

- Capable of giving signed informed consent that includes compliance with the
requirements and restrictions listed in the consent form and in the protocol

- Alanine aminotransferase (ALT), alkaline phosphatase, and bilirubin <=1.5x Upper
Limit of Normal (ULN ) (isolated bilirubin >1.5xULN is acceptable if bilirubin is
fractionated and direct bilirubin <35%).

Exclusion Criteria:

- Current or chronic history of liver disease, or known hepatic or biliary
abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).

- History of clinically significant cardiovascular disease including:

- Exclusion criteria for screening electrocardiogram ([ECG] a single repeat is
allowed for eligibility determination) showing <45 and >100 beats per minute in
males and <50 and >100 beats per minute in females; >120 msec of QRS duration
for both males and females; and >450 msec of QTcF interval for both males and
females

- Evidence of previous myocardial infarction (pathologic Q waves, S T segment
changes [except early repolarization])

- History/evidence of symptomatic arrhythmia, angina/ischemia, coronary artery
bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty
(PCTA) or any clinically significant cardiac disease

- Any conduction abnormality (including but not specific to left or right complete
bundle branch block, atrioventricular block (AV) block (2nd degree [Type II] or
higher), Wolf Parkinson White [WPW] syndrome)

- Sinus pauses > 3 seconds

- Any significant arrhythmia which, in the opinion of the principal investigator
and GSK medical monitor, will interfere with the safety for the individual
subject

- Non sustained (>=3 consecutive ventricular ectopic beats) or sustained
ventricular tachycardia

- History of inflammatory bowel disease

- History of cholecystectomy or other gastrointestinal surgery (except appendectomy
more than three months prior to study)

- History of peptic ulceration or pancreatitis within the preceding 6 months of
screening

- History of ongoing or clinically relevant seizure disorder within the previous 2
years, including subjects who have required treatment for seizures within this time
period. A prior history of seizure, with a seizure free period of at least 2 years,
off antiepileptics, may be considered for enrolment if the investigator believes the
risk of seizure recurrence is low. All cases of prior seizure history should be
discussed with the medical monitor prior to enrolment

- Any other medical condition which, in the judgment of the investigator and medical
monitor, could jeopardize the integrity of the data derived from that subject or the
safety of the subject. This includes but is not limited to any pre existing condition
that interferes with normal gastrointestinal anatomy or motility that could interfere
with the absorption, metabolism, and/or excretion of the study drug.

- Unable to refrain from the use of prescription or non prescription drugs, including
vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or
14 days if the drug is a potential enzyme inducer) or 5 half lives (whichever is
longer) prior to the first dose of study medication, unless in the opinion of the
investigator and GSK medical monitor the medication will not interfere with the study
procedures or compromise subject safety.

- History of regular alcohol consumption within 6 months of the study defined as an
average weekly intake of >14 drinks for males or >7 drinks for females. One drink is
equivalent to 12 grams of alcohol: 12 ounces (360 milliliters (mL) of beer, 5 ounces
(150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits

- Urinary cotinine levels indicative of smoking or history or regular use of tobacco or
nicotine containing products within 30 days prior to screening.

- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy that, in the opinion of the investigator or medical
monitor, contraindicates their participation.

- Positive hepatitis B surface antigen (HBsAg), or a positive hepatitis B core antibody
(HBcAb) with a negative hepatitis B surface antibody (HBsAb) at screening or within 3
months prior to first dose of study treatment.

- Positive hepatitis C antibody test result at screening or within 3 months prior to
first dose of the study treatment.

- A positive pre study drug/alcohol screen.

- A positive test for HIV antibody.

- Where participation in the study would result in donation of blood or blood products
in excess of 500 mL within a 56 day period.

- The subject's systolic blood pressure is outside the range of 90 to 140 millimeters
of mercury (mmHg), or diastolic blood pressure is outside the range of 45 to 90 mmHg

- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half lives or twice the duration of the biological effect of the
investigational product (whichever is longer); however, the subject should not be
participating in another clinical trial at the time of screening, and by the time of
first dosing should not be within the time periods listed above

- Exposure to more than four new chemical entities within 12 months prior to the first
dosing day